Tempus AI (TEM) stock pops again as new cancer algorithm, analyst calls hit ahead of earnings
Tempus AI shares rose about 1.2% to $56.81 in premarket trading Thursday after a 6.9% gain Wednesday. The company launched an HRD-RNA algorithm to identify cancer patients likely to respond to certain drugs. Mizuho and Baird began coverage with Outperform ratings and bullish price targets. The new algorithm is available for research use only, with clinical rollout expected later this year.